Abstract: Objective To explore the pathogenesis of drug-induced liver injury in the treatment of autoimmune diseases, and to provide references for rational clinical use. Methods CNKI, Wanfang Data, PubMed and other databases were searched for literature on the mechanisms of drug-induced liver injury associated with drugs used in the treatment of autoimmune diseases, including methylprednisolone, methotrexate, infliximab, and adalimumab. The search focused on two categories: traditional drugs, as well as biologics and small molecule inhibitors. Results The mechanisms of liver injury caused by different classes of autoimmune disease drugs varied. However, most of these drugs led to an increase in one or more liver cell enzymes. For some drugs, the underlying mechanism of drug-induced liver injury remained unclear. Conclusion The incidence of drug-induced liver injury associated with drugs used to treat autoimmune diseases is closely linked to the characteristics of the drugs and the individual differences between patients. Clinical follow-up should be ensured, and liver function should be monitored.

Key words: Autoimmune Diseases, Drug-Induced Liver Injury, Liver Cell Enzymes, Methotrexate, Infliximab, Adalimumab, Adverse Drug Reaction